Abstract:Chengwu Gong, 1, * Jiyuan Ai, 1, * Yun Fan, 2 Jun Gao, 1 Weiwei Liu, 1 Qian Feng, 3 Wenjun Liao, 1 Linquan Wu 1 1 Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, People's Republic of China; 2 Department of Neurology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430000, People's Republic of China; 3 Department of Emergency Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, People's Republic of China *These authors contributed equally to this work Correspondence: Linquan Wu; Wenjun Liao Department of General Surgery, The Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Nanchang 330006, People's Republic of China Tel +86 791 86311529 Fax +86 791 86262262 Email wulqnc@163.com; liaowenjun120@163.com Purpose: Studies show that high expression of non-SMC condensin I complex subunit G (NCAPG) is associated with many tumors. In this study, we explore the mechanism by which NCAPG promotes proliferation in hepatocellular carcinoma (HCC). Patients and methods: Liver cancer and paracancerous tissue specimens of 90 HCC patients were collected, and expression levels of NCAPG in these tissues and cell lines were evaluated by Western blotting and immunohistochemistry. HCC cells were transfected with siRNAs and plasmids, and pathway activators or inhibitors were added. The 5-ethynyl-2ʹ-deoxyuridine (EdU) proliferation assay was used to measure cell proliferation. Flow cytometry was used to evaluate cell apoptosis. Western blot assays were performed as a standard procedure to detect total protein expression. Treated HCC cells were subcutaneously injected into nude mice. Results: Analysis using the Oncomine database showed that NCAPG was upregulated in HCC and immunohistochemistry and Western blot assays showed it was upregulated in both HCC tissues and HCC cell lines. The overexpression of NCAPG could promote HCC cell proliferation and reduce HCC cell apoptosis. More importantly, RNA-sequencing analysis predicted that NCAPG plays a role in the HCC via PI3K-AKT signaling pathway. The PI3K/AKT/FOXO4 pathway was aberrantly activated, and the expressions of apoptosis-related protein were altered when NCAPG was overexpressed or silenced both in vitro and in vivo. LY294002, a PI3K inhibitor, could eliminate the NCAPG role of promoting HCC cell proliferation and reducing HCC cell apoptosis, while 740Y-P, a PI3K activator, contributed to the opposite effect. Conclusion: NCAPG functions as an oncogene in HCC and plays a role in promoting cell proliferation and antiapoptosis through activating the PI3K/AKT/FOXO4 pathway. Keywords: NCAPG, hepatocellular carcinoma, PI3K/AKT, FOXO4, proliferation

NCAPG promotes proliferation of epithelial ovarian cancer by activating the NF-κB and AKT/mTOR pathways

High Expression of ENPP1 in High-Grade Serous Ovarian Carcinoma Predicts Poor Prognosis and As a Molecular Therapy Target.

NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway

Inhibition of NCAPG expression inactivates the Wnt/β‐catenin signal to suppresses endometrial cancer cell growth in vitro

NCAPG Induces Cell Proliferation in Cardia Adenocarcinoma via PI3K/AKT Signaling Pathway

NCAPG, Mediated by Mir-378A-3p, Regulates Cell Proliferation, Cell Cycle Progression, and Apoptosis of Oral Squamous Cell Carcinoma Through the GSK-3β/β-catenin Signaling.

NCAPG facilitates colorectal cancer cell proliferation, migration, invasion and epithelial–mesenchymal transition by activating the Wnt/β-catenin signaling pathway

NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression

KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a

Overexpressed MAGP1 is Associated with a Poor Prognosis and Promotes Cell Migration and Invasion in Gastric Cancer

NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma

MicroRNA-520g Promotes Epithelial Ovarian Cancer Progression and Chemoresistance Via DAPK2 Repression

Increased endogenous PKG I activity attenuates EGF-induced proliferation and migration of epithelial ovarian cancer via the MAPK/ERK pathway

NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling

NCAPG is a Promising Therapeutic Target Across Different Tumor Types

PGRN Promotes Migration and Invasion of Epithelial Ovarian Cancer Cells Through an Epithelial Mesenchymal Transition Program and the Activation of Cancer Associated Fibroblasts.

NCAPH is upregulated in endometrial cancer and associated with poor clinicopathologic characteristics

LncRNA PCGEM1 Induces Ovarian Carcinoma Tumorigenesis and Progression Through RhoA Pathway

NCAPG2 Promotes Tumour Proliferation by Regulating G2/M Phase and Associates with Poor Prognosis in Lung Adenocarcinoma

Genome-wide CRISPR Knockout Screens Identify NCAPG As an Essential Oncogene for Hepatocellular Carcinoma Tumor Growth

NCAPG2 Could Be an Immunological and Prognostic Biomarker: from Pan-Cancer Analysis to Pancreatic Cancer Validation